Synthetix Inc. DBA Helix Chemical Supply
Has Synthetix Inc. DBA Helix Chemical Supply received an FDA warning letter about GLP-1 drugs?
Yes. FDA issued Synthetix Inc. DBA Helix Chemical Supply a warning letter naming semaglutide and tirzepatide, dated Feb 7, 2024, with the FDA subject line “Unapproved New Drugs/Misbranded.”
FDA records in this index name Synthetix Inc. DBA Helix Chemical Supply on Feb 7, 2024.
- Websites the letters name
- helixchem.com (see how each letter refers to them)
- Type named in FDA records
- Not stated
- FDA warning letters
- 1
- Drug recall reports
- 0
- Drugs named
- Semaglutide, Tirzepatide
- Latest record
- Feb 7, 2024
FDA warning letters
| Later letters FDA lists | Letter | |||
|---|---|---|---|---|
| Feb 7, 2024 | Unapproved New Drugs/Misbranded | Semaglutide, Tirzepatide | None listed by FDA as of Nov 15, 2026 | fda.gov |
A warning letter states FDA’s view when it was issued; it is not a court finding, and the company may have responded since. The later-letters column repeats what FDA’s warning letter index lists for each letter.
FDA’s summary excerpts
- Feb 7, 2024: … in October 2023 and has observed that your website offers “ Semaglutide ” and “Tirzepatide” products for sale in the United States. As described below, your “ Semaglutide ” and “Tirzepatide” products are unapproved new … Act), 21 U.S.C. 355(a) and 301(d). Furthermore, your “ Semaglutide ” and “Tirzepatide” products are misbranded drugs … Full letter
Websites named in the letters
Each letter below is addressed to the firm FDA names in it, not to a website. The sentence quoted is the letter’s own reference to the site, copied from the letter on fda.gov.
- helixchem.com: FDA’s warning letter of Feb 7, 2024 is addressed to Synthetix Inc. DBA Helix Chemical Supply. It refers to the site in these words: “This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website at the Internet address www.helixchem.com in October 2023 and has observed that your website offers “Semaglutide” and “Tirzepatide” products for sale in the United States.” Full letter
Drug recalls
No openFDA drug recall reports in this index.
This page lists public regulatory records as published by the issuing agency. A record is not a finding by this site. A warning letter states the agency’s view at the time it was issued; companies may have responded or corrected the issue since. Follow each link for the original document and any close-out letter. Report an error or add a company response.
Sources
Records last pulled Nov 15, 2026. Every entry links to the original public record.